The advantages of non-invasive cancer testing are well known, yet routine clinical implementation is still a long way off. Despite recent advances in the space, researchers and clinicians alike are still on the hunt for a standardised clinical procedure (coupled with effective data handling) that can be effectively integrated into routine screening programmes. The question remains: how can we ensure liquid biopsies are successfully translated to clinical practice and enable huge potential gains for patients?
Join us for Liquid Biopsy ONLINE, a 3-part webinar series where we’ll discuss how liquid biopsies can be optimised to ensure appropriate sensitivity and selectivity for effective clinical monitoring. Ultimately, this will shed light on the next steps required to move liquid biopsies from the research lab into the clinic.
– – – – –
Thursday 6th October 2022 – 3pm BST/ 4pm CET/ 10am EDT
Liquid biopsies allow clinicians to use routine blood monitoring to assess patient treatment responses, monitor recurrence, measure residual disease, and ultimately improve clinical decision making. With so many opportunities to leverage molecular data from a blood draw, why are we not arming clinicians with this information on a more regular basis?
This webinar will explore the application of liquid biopsies for effective patient monitoring in the clinic, and how we can get these tests into the hands of clinicians faster.
- ctDNA for early detection of cancer and recurrence
- Dr. Aadel Chaudhuri, Assistant Professor of Radiation Oncology, University of Washington.
- The Future of Liquid Biopsies: Creating Standards and Overcoming Challenges
- Lauren Leiman, Executive Director, BLOODPAC.
- Engaging the Clone Wars: Clinical Utility of the Watch and Switch Strategy in the PADA-1 Trial
- Francois-Clement Bidard, Professor of Medical Oncology and Head of Breast Cancer Group, Institut Curie.
– – – – –
Webinar 2: Optimising biomarker selection and monitoring to employ the use of liquid biopsies to improve patient responses in clinical trials
Thursday 13th October 2022 – 3pm BST/ 4pm CET/ 10am EDT
The heterogenicity of tumours makes a one-size-fits-all approach to cancer diagnosis and screening impossible. Instead, personalised patient monitoring using liquid biopsies could be the route forward. However, the particularly low abundance of tumour-associated biomarkers in the blood makes this technology akin to “finding a needle in a haystack,” and incurs the risk of false negatives.
This webinar will focus on the potential measures being used to improve the scientific vigour of liquid biopsies and how selecting the correct biomarkers will aid this process.
- Single-Cell and Extracellular Vesicle Profiling
- Jina Ko, Assistant Professor, Department of Bioengineering, University of Pennsylvania.
- Epigenetics in Liquid Biopsy for the Management of Cancer Patients
- Simon Joosse,Associate Professor and Group Leader at The Department of Tumour Biology, University Medical Centre Hamburg.
- A Technical and Clinical Overview of Using ctDNA in Early-Stage Lung Cancer and Implications for Clinical Trials
- Chris Abbosh, Senior Director in Translational Medicine, AstraZeneca.
– – – – –
Webinar 3: Implementing the routine use of liquid biopsies into the clinic and its implications on precision medicine
Thursday 20th October 2022 – 3pm BST/ 4pm CET/ 10am EDT
Liquid biopsies entered the clinical scene with the promise of revolutionising cancer diagnosis and monitoring. However, key steps must still be taken to establish a standardised procedure with distinct clinical endpoints and progress the technology from mere concept to routine clinical use.
This webinar will focus on the steps that must be taken to integrate liquid biopsies into clinical practice, including an assesment of where we currently stand along this journey.
- Liquid Biopsy: From Discovery to Clinical Application
- Dr. Catherine Alix-Panabieres, Director of the LCCRH, University Medical Centre of Montpellier.
- The Potential of Liquid Biopsy for the Management of Cancer Patients
- Evi Lianidou, Professor of Analytical Chemistry, University of Athens.
- Comprehensive Genomic Profiling (CGP) of ctDNA for Guiding Treatment Decisions in Advanced Cancer
- Samantha Hasenleithner, Diagnostic and Research Institute of Human Genetics, Medical University of Graz.
– – – – –